

10/071,032

- 40 -

Dyer et al.

REMARKS

Applicants note with appreciation that Claims 4, 10, 15, 17 to 20 and 35 are allowed.

Claim Status

Claims 4, 10, 15-20 and 35 are pending.

Claims 1-3, 5-9, 11-14, 21-34 and 36-44 have been cancelled.

Claims 4, 15-20 and 35 have been amended.

35 U.S.C. § 112

Claims 3, 11, 21, 26, 27, 29, 32, 38, 43, and 44 have been rejected under 35 U.S.C. 112, second paragraph.

Claims 3, 11, 21, 26, 27, 29, 32, 38, 43, and 44 have been canceled rendering this rejection moot.

35 U.S.C. § 102(e)

Claims 3, 11, 12, 14, 16, 21, 26, 27, 29, 32, 38, 43, and 44 have been rejected under 35 U.S.C. § 102(e) as allegedly being anticipated by Andrianjara *et al.* Claims 3, 11, 12, 14, 21, 26, 27, 29, 32, 38, 43, and 44 have been canceled rendering this rejection moot with respect to these claims.

Applicants respectfully submit that claim 16 is patentable over Andrianjara *et al.* because the compound mentioned in the rejection (Synthesis Example 5) was not disclosed in the priority document (60/268,821) filed February 14, 2001. Therefore, this compound is entitled to the filing date of the PCT application, which is February 13, 2001. The present application was filed on February 8, 2001, which is before the filing date of the PCT application. In view of the remarks made above, Applicants respectfully request withdrawal of this rejection with regard to claim 16.

10/071,032

- 41 -


Dyer et al.

Conclusion

In view of the amendments and remarks made above, Applicants respectfully requests reconsideration and allowance of Claims 4, 10, 15-20 and 35.

Respectfully submitted,

Date: 9/29/2005



Todd M. Crissey
Reg. No. 37,807
Pfizer, Inc.
2800 Plymouth Road
Ann Arbor, MI 48105
Tel. (734) 622-7813
Fax (734) 622-1553